Renin-angiotensin system inhibition reverses the altered triacylglycerol metabolic network in diabetic kidney disease

[1]  H. V. Jagadish,et al.  Gene expression profiles of diabetic kidney disease and neuropathy in eNOS knockout mice: Predictors of pathology and RAS blockade effects , 2021, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  L. Liang,et al.  Maternal triacylglycerol signature and risk of food allergy in offspring. , 2019, The Journal of allergy and clinical immunology.

[3]  G. Michailidis,et al.  Increased lipogenesis and impaired β-oxidation predict type 2 diabetic kidney disease progression in American Indians. , 2019, JCI insight.

[4]  L. Liang,et al.  Maternal triacylglycerol signature and risk of food allergy in offspring. , 2019, The Journal of allergy and clinical immunology.

[5]  George Michailidis,et al.  Differential network enrichment analysis reveals novel lipid pathways in chronic kidney disease , 2019, Bioinform..

[6]  L. Liang,et al.  Lipid metabolic networks, Mediterranean diet and cardiovascular disease in the PREDIMED trial. , 2018, International journal of epidemiology.

[7]  L. Yang,et al.  Risk factors of chronic kidney diseases in Chinese adults with type 2 diabetes , 2018, Scientific Reports.

[8]  Canan Has,et al.  Identification of key lipids critical for platelet activation by comprehensive analysis of the platelet lipidome. , 2018, Blood.

[9]  G. Michailidis,et al.  Lipidomics and Biomarker Discovery in Kidney Disease. , 2018, Seminars in nephrology.

[10]  Subramaniam Pennathur,et al.  Impaired β-Oxidation and Altered Complex Lipid Fatty Acid Partitioning with Advancing CKD. , 2017, Journal of the American Society of Nephrology : JASN.

[11]  H. V. Jagadish,et al.  Shared and distinct lipid-lipid interactions in plasma and affected tissues in a diabetic mouse model[S] , 2017, Journal of Lipid Research.

[12]  R. MacIsaac,et al.  Clinical predictive factors in diabetic kidney disease progression , 2016, Journal of diabetes investigation.

[13]  Mark Woodward,et al.  Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus , 2016, Circulation.

[14]  Jiang He,et al.  Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort , 2016, Kidney international reports.

[15]  D. Gordin,et al.  The Presence and Consequence of Nonalbuminuric Chronic Kidney Disease in Patients With Type 1 Diabetes , 2015, Diabetes Care.

[16]  Dean P. Jones,et al.  The effects of age and dietary restriction on the tissue-specific metabolome of Drosophila , 2015, Aging cell.

[17]  Kerri J Grove,et al.  Diabetic nephropathy induces alterations in the glomerular and tubule lipid profiles1[S] , 2014, Journal of Lipid Research.

[18]  T. Spector,et al.  Lipidomics Profiling and Risk of Cardiovascular Disease in the Prospective Population-Based Bruneck Study , 2014, Circulation.

[19]  U. Patel,et al.  Cardiovascular complications of diabetic kidney disease. , 2014, Advances in chronic kidney disease.

[20]  F. Sacks,et al.  Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy in Type 2 Diabetes Mellitus: A Global Case–Control Study in 13 Countries , 2013, Circulation.

[21]  Yang Zhang,et al.  Interaction of RAS Activation and Lipid Disorders Accelerates the Progression of Glomerulosclerosis , 2013, International journal of medical sciences.

[22]  Oliver Fiehn,et al.  LipidBlast - in-silico tandem mass spectrometry database for lipid identification , 2013, Nature Methods.

[23]  R. Nelson,et al.  Hyperlipidemia as a risk factor for cardiovascular disease. , 2013, Primary care.

[24]  B. Kestenbaum,et al.  Kidney disease and increased mortality risk in type 2 diabetes. , 2013, Journal of the American Society of Nephrology : JASN.

[25]  C. Tseng,et al.  Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. , 2013, The review of diabetic studies : RDS.

[26]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[27]  R. Harris,et al.  Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice. , 2012, American journal of physiology. Renal physiology.

[28]  Kim Ekroos,et al.  High throughput quantitative molecular lipidomics. , 2011, Biochimica et biophysica acta.

[29]  S. Carr,et al.  Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. , 2011, The Journal of clinical investigation.

[30]  Kazuki Saito,et al.  Compensation for systematic cross-contribution improves normalization of mass spectrometry based metabolomics data. , 2009, Analytical chemistry.

[31]  M. Kretzler,et al.  Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. , 2008, American journal of physiology. Renal physiology.

[32]  R. Harris,et al.  Endothelial nitric oxide synthase deficiency produces accelerated nephropathy in diabetic mice. , 2006, Journal of the American Society of Nephrology : JASN.

[33]  Kai Simons,et al.  Automated identification and quantification of glycerophospholipid molecular species by multiple precursor ion scanning. , 2006, Analytical chemistry.

[34]  G. Remuzzi,et al.  Preventing microalbuminuria in type 2 diabetes. , 2004, The New England journal of medicine.

[35]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[36]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[37]  H. Parving,et al.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.

[38]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[39]  J. Sowers,et al.  Diabetes and cardiovascular disease. , 1999, Diabetes care.

[40]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[41]  N. Altman.  An Introduction to Kernel and Nearest-Neighbor Nonparametric Regression , 1992 .

[42]  Daniel L. McGee,et al.  Diabetes and cardiovascular disease. The Framingham study. , 1979, JAMA.

[43]  D L McGee,et al.  Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study , 1979, Diabetes Care.

[44]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[45]  J. Moreton.  Atherosclerosis and Alimentary Hyperlipemia. , 1947, Science.